Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares Repurchased
Ratios

Ligand Pharmaceuticals (LGND) Shares Repurchased (2017 - 2020)

Ligand Pharmaceuticals' Shares Repurchased history spans 8 years, with the latest figure at $4.7 million for Q4 2020.

  • For Q4 2020, Shares Repurchased fell 94.25% year-over-year to $4.7 million; the TTM value through Sep 2021 reached $4.7 million, down 96.97%, while the annual FY2025 figure was $15.0 million, N/A changed from the prior year.
  • Shares Repurchased for Q4 2020 was $4.7 million at Ligand Pharmaceuticals, down from $73.3 million in the prior quarter.
  • Across five years, Shares Repurchased topped out at $181.2 million in Q3 2019 and bottomed at $502000.0 in Q1 2016.
  • The 5-year median for Shares Repurchased is $50.8 million (2018), against an average of $59.7 million.
  • The largest annual shift saw Shares Repurchased soared 7899.21% in 2019 before it crashed 94.25% in 2020.
  • A 5-year view of Shares Repurchased shows it stood at $502000.0 in 2016, then skyrocketed by 291.63% to $2.0 million in 2017, then skyrocketed by 3467.7% to $70.1 million in 2018, then rose by 16.82% to $81.9 million in 2019, then plummeted by 94.25% to $4.7 million in 2020.
  • Per Business Quant, the three most recent readings for LGND's Shares Repurchased are $4.7 million (Q4 2020), $73.3 million (Q1 2020), and $81.9 million (Q4 2019).